Twist Bioscience Co. (NASDAQ:TWST - Get Free Report) CFO Adam Laponis sold 856 shares of Twist Bioscience stock in a transaction that occurred on Wednesday, October 9th. The stock was sold at an average price of $41.81, for a total value of $35,789.36. Following the sale, the chief financial officer now directly owns 73,397 shares of the company's stock, valued at approximately $3,068,728.57. The trade was a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which can be accessed through the SEC website.
Twist Bioscience Stock Up 6.8 %
Shares of TWST stock opened at $44.47 on Friday. The firm has a market capitalization of $2.61 billion, a P/E ratio of -11.64 and a beta of 1.77. Twist Bioscience Co. has a twelve month low of $14.42 and a twelve month high of $60.90. The stock's fifty day simple moving average is $43.88 and its 200 day simple moving average is $43.89.
Twist Bioscience (NASDAQ:TWST - Get Free Report) last released its quarterly earnings results on Friday, August 2nd. The company reported ($1.47) EPS for the quarter, missing analysts' consensus estimates of ($0.76) by ($0.71). Twist Bioscience had a negative net margin of 74.63% and a negative return on equity of 32.17%. The company had revenue of $81.50 million during the quarter, compared to the consensus estimate of $77.40 million. During the same quarter last year, the firm posted ($1.01) EPS. The company's quarterly revenue was up 27.7% on a year-over-year basis. As a group, equities research analysts expect that Twist Bioscience Co. will post -3.13 EPS for the current fiscal year.
Analysts Set New Price Targets
Tim Sykes’ Urgent Trade Alert: “Make this move now”
From Timothy Sykes | Ad
WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock
This $2 trillion D.C. shock is NOT about Trump or Biden dropping out of the race…
Click here to see a unique election-year trade
Several research firms recently weighed in on TWST. JPMorgan Chase & Co. lifted their price target on Twist Bioscience from $28.00 to $35.00 and gave the stock an "underweight" rating in a report on Monday, August 5th. Evercore ISI lifted their price objective on Twist Bioscience from $52.00 to $56.00 and gave the company an "outperform" rating in a report on Tuesday, October 1st. Robert W. Baird lifted their price objective on Twist Bioscience from $40.00 to $46.00 and gave the company an "outperform" rating in a report on Monday, August 5th. Barclays dropped their price objective on Twist Bioscience from $60.00 to $55.00 and set an "overweight" rating for the company in a report on Monday, August 5th. Finally, The Goldman Sachs Group lifted their price objective on Twist Bioscience from $45.00 to $55.00 and gave the company a "buy" rating in a report on Tuesday, July 9th. One equities research analyst has rated the stock with a sell rating and seven have issued a buy rating to the company. According to data from MarketBeat.com, Twist Bioscience presently has an average rating of "Moderate Buy" and a consensus target price of $51.63.
View Our Latest Research Report on Twist Bioscience
Institutional Investors Weigh In On Twist Bioscience
A number of institutional investors have recently made changes to their positions in TWST. Virtu Financial LLC bought a new stake in shares of Twist Bioscience in the 4th quarter valued at about $526,000. China Universal Asset Management Co. Ltd. grew its position in shares of Twist Bioscience by 66.3% in the 1st quarter. China Universal Asset Management Co. Ltd. now owns 11,101 shares of the company's stock valued at $381,000 after buying an additional 4,427 shares during the last quarter. Principal Financial Group Inc. grew its position in shares of Twist Bioscience by 151.2% in the 1st quarter. Principal Financial Group Inc. now owns 39,624 shares of the company's stock valued at $1,360,000 after buying an additional 23,850 shares during the last quarter. Baillie Gifford & Co. lifted its stake in shares of Twist Bioscience by 12.1% in the 1st quarter. Baillie Gifford & Co. now owns 1,227,528 shares of the company's stock valued at $42,116,000 after purchasing an additional 132,770 shares during the period. Finally, Mirae Asset Global Investments Co. Ltd. lifted its stake in shares of Twist Bioscience by 30.7% in the 1st quarter. Mirae Asset Global Investments Co. Ltd. now owns 156,288 shares of the company's stock valued at $5,362,000 after purchasing an additional 36,744 shares during the period.
Twist Bioscience Company Profile
(
Get Free Report)
Twist Bioscience Corporation engages in the manufacture and sale of synthetic DNA-based products. The company offers synthetic genes and gene fragments used in product development for therapeutics, diagnostics, chemicals/materials, food/agriculture, data storage, and various applications within academic research by biotech, pharma, industrial chemical, and agricultural companies, as well as academic labs; Oligo pools used in targeted NGS, CRISPR gene editing, mutagenesis experiments, DNA origami, DNA computing, data storage in DNA, and other applications; and immunoglobulin G proteins for customers focused on the pursuit of drug discovery and development.
See Also
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. This story was reviewed by InsiderTrades.com's editorial team prior to publication. Please send any questions or comments about this story to [email protected].
